The Economist

Advertisment

The case for Easter eggs and other treats

HAVE YOU ever actually read a terms-and-conditions document? WordPress, a service for building websites whose clients include the White House and Disney, thinks anyone who has deserves congratulations. Its terms of service...

America has a plan to throttle Chinese chipmakers

MAKING CHIPS is complex work. Semiconductor manufacturers such as Intel, Samsung and TSMC themselves rely on machine tools built by an array of firms that are far from household names. The equipment...

Elon Musk is taking Twitter’s “public square” private

ELON MUSK, the world’s richest man, has described Twitter as the “de facto public town square”. On April 25th he struck a deal to take it private in what will be one...

The finance secrets of big tech

AMERICA’S TECH giants make ungodly amounts of money. In 2021 the combined revenue of Alphabet, Amazon, Apple, Meta and Microsoft reached $1.4trn. These riches come from a wide and constantly expanding set...

Elon Musk’s Twitter saga is capitalism gone rogue

Editor’s note (April 21st 2022): After this article was published, Elon Musk said he has received funding to finance a takeover of Twitter, and that he is exploring whether to launch a...

Netflix sheds subscribers—and $170bn in market value

IN JANUARY NETFLIX warned investors that it expected to add only 2.5m subscribers in the quarter ahead, causing a sell-off that knocked nearly 30% off its share price. On April 19th the...

Startups for the modern workplace

GREAT UPHEAVALS always spark innovation. The covid-19 pandemic is no different. The share of new patent applications in America connected to remote-working technologies more than doubled between January and September 2020. Opportunities...

Annual meetings are the new frontline in the battle over corporate purpose

COMPANIES HAVE always had to answer to their investors. But these days shareholders have new questions—lots of them. On April 28th shareholders in three big drug companies, Johnson & Johnson (J&J), Moderna...

The Economist

Advertisment